News

Data presented at the 2018 American Association for Cancer Research Annual Meeting show that a new combination could provide long-term, systemic responses in patients with advanced melanoma.

Treatment now offers an individualized approach to control bleeding in appropriate patients undergoing surgery.

The therapy, when used prophylactically either weekly or biweekly, showed a statistically significant reduction in treated bleeds in comparison to no prophylaxis.

This morning, the U.S. FDA provided full approval to Boehringer Ingelheim for idarucizumab (Praxbind), its specific reversal agent for dabigatran etexilate mesylate (Pradaxa).

In 90 patients that received idarucizumab in the RE-VERSE AD phase 3 trial, the median maximum percentage reversal was 100%.

An Alzheimer’s diagnosis may cause fear, but the broad spectrum of cognitive impairment means some physicians can continue to practice despite the disease.

Current research shows that positive parenting strategies are linked with improved social-emotional development, but gaps in analysis persist.

The likelihood that a patient would receive a new opioid prescription was higher for at-risk patients and remained true even after adjusting for demographic characteristics, comorbidities, and diagnoses associated with pain.

The therapy, FX1a inhibitor BMS-986177, will advance to phase 2 clinical trials for wider indications.

FDA approves the development of VAR 200 for the treatment of focal segmental glomerulosclerosis (FSGS) in adults.

FDA exercises enforcement discretion regarding its ExeGen ATM MiniSwine model, clearing the genetically engineered (GE) to model ataxia telangiectasia (AT) for commercial use as a research tool.

Irritability was associated with widespread neural activation or increased activity in the insula, caudate, dorsolateral and ventrolateral prefrontal cortex, and inferior parietal lobule.

This morning, Galapagos announced the design of its global Phase 3 program of GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF).

Transgender/gender-nonconforming youth may present with mental health conditions that require immediate evaluation and implementation gender identity support measures.

The angle of the superior cerebellar artery outlet can be useful for monitoring the progression of basilar artery dolichoectasia in patients with Pompe, according to results in the Orphanet Journal of Rare Diseases.

Mobile apps have a high potential for improving treatment adherence, but rigorous testing is still needed to determine efficacy.

The benefit for patients without diabetes was +0.3 ml/min/1.73 m2 per year and for those with concurrent diabetes, the benefit was doubled to +.06 ml/min/1.73 m2.

The NDA acceptance comes just days after the FDA issued a Refusal to File letter to Alkermes for its investigational MDD therapy.

Positive clinical results from Phase 1 and Phase 1/2 open-label extension studies of givosiran were presented by Alnylam at the European Association for the Study of the Liver 53rd Annual International Liver Congress.

While pre-pregnancy blood pressure can impact pregnancy outcomes, targeted lifestyle interventions could be utilized to favorably impact reproductive health.

Patients receiving long-term care more likely to test positive for VRE than toxigenic C. difficile.

No linear association was found between CD4 cell count and blood pressure after adjusting for important confounders in patients with HIV.

Patients who consumed vinegar daily along with a restricted calorie diet lost more weight and saw improved BMI scores compared to those just on the diet.

James Stankiewicz, MD, discussed the current state of care in MS, what's in the pipeline, the advances that have been made, and what still remains to be done.

On Thursday, GlaxoSmithKline (GSK) announced that it will be transferring its portfolio of approved and investigational gene therapies to Orchard Therapeutics in exchange for a 19.9% stake in the company.

Positive pre-clinical data is released regarding BGB601 for the treatment of fibrosis, idiopathic pulmonary fibrosis (IPF), and non-alcoholic steatohepatitis (NASH).

The therapy regimen is tolerable, safe, and effective for patients attempting to detoxify for an extended opioid agonist treatment.

NGM Bio announced this morning that it will be highlighting data from its Phase 2 clinical trial of NGM282 in patients with primary sclerosing cholangitis at The International Liver Congress.

Deborah Brown, Chief Mission Officer of the American Lung Association (ALA), discusses the ALA’S most recent LUNG FORCE Expo in Cherry Hill, New Jersey, 2018.